Everlab Raises US$10 Million to Scale AI-Driven Preventive Health Platform Globally

Everlab, the AI-powered health platform reimagining preventive care, announced a US$10 million (AU$15 million) seed round led by global growth equity fir...

July 22, 2025 | Tuesday | News
Corteria Pharmaceuticals Advances Dual CRF2 Agonist Pipeline for Heart Failure and Obesity

Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, ...

July 22, 2025 | Tuesday | News
Trethera’s TRE-515 Receives FDA Fast Track Designation for Advanced Prostate Cancer Treatment

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...

July 11, 2025 | Friday | News
Angelini Ventures Co-Leads CHF79M Series B in NUCLIDIUM to Advance Copper-Based Radiotheranostics

  Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech a...

July 11, 2025 | Friday | News
Ascentage Pharma Secures China’s First Approval for Bcl-2 Inhibitor in CLL/SLL with Lisaftoclax

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it...

July 11, 2025 | Friday | News
SimBioSys Secures Third FDA Clearance for TumorSight™ Viz to Advance Precision in Breast Cancer Surgery

SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, today announced its third FDA 510(k) c...

July 10, 2025 | Thursday | News
Purespring Therapeutics Receives FDA Clearance to Initiate Clinical Trials for IgA Nephropathy Gene Therapy

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, announces that the U.S. Food and Drug A...

July 10, 2025 | Thursday | News
Longeveron Receives FDA Clearance to Begin Phase 2 Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy

 Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

July 09, 2025 | Wednesday | News
Japan’s Chugai and Singapore’s Gero Join Forces to Advance Antibody Therapies Targeting Aging via AI and Human Data

Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through...

July 08, 2025 | Tuesday | News
Orchard Therapeutics Completes Global Enrollment in Pivotal MPS-IH Gene Therapy Trial Ahead of Schedule

Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...

July 08, 2025 | Tuesday | News
Johnson & Johnson Submits EMA Application to Broaden AKEEGA® Use in HRR‑Mutated Metastatic Hormone‑Sensitive Prostate Cancer

The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or predn...

July 07, 2025 | Monday | News
Masitinib Receives FDA and EMA Authorisation for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate Cancer

MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIE...

July 07, 2025 | Monday | News
Alvotech and Advanz Pharma Forge Agreement to Commercialise Biosimilar Candidate to Cimzia® Across Europe

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...

July 02, 2025 | Wednesday | News
Addex Therapeutics Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine for Autism and Neuropsychiatric Disorders

Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

July 01, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close